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The Genetics of Cancer Susceptibility
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Cancer is considered to be a multifactorial disease in which a host cell is transformed from normal to malignant as a result of complex interactions of
external (environmental) stimuli and cancer-predisposing or cancer-suppressing genes. Although certain chemical carcinogens and ionizing radiation
are known to cause specific alterations at the level of the gene, other correlations are less clear. Not infrequently, cancer is found to aggregate in
families in an apparently nonrandom fashion. It has been through the study of such families that our understanding of the genetic events leading to
cancer has developed. Both common and rare tumors may occur together in familial-cancer families. Frequently, tumors occur at an earlier age than
one would expect in the general population; often, multiple tumors of different organs develop in a particular affected family member. Recent
advances in the genetics of familial cancer syndromes have led to the possibility to perform genetic testing on unaffected relatives who might carry
a genetic defect that predisposes them to cancer. Complex ethical, social, and legal implications arise from these new technical advances.
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Introduction
For many cancers, etiologic environmental
associations are well documented. The link
between smoking and lung cancer is well
described. It is suspected that dietary prac-
tices have much to do with the global vari-
ation in the incidence ofcarcinomas ofthe
stomach and colon. The hepatitis B virus
and exposure to aflotoxin may be major
etiologic agents for primary liver carci-
noma, and a variety of etiologic associa-
tions have been causally associated with
breast cancer. It will be noted, however,
that the majority of those cancers associ-
ated with exposures to environmental
agents are typically of adult onset. Weaker
epidemiologic associations of ionizing
radiation and cancers of the hematopoietic
systems and brain tumors, as well as dis-
crepant observations linking electromag-
netic fields with leukemogenesis in children
have been made. In most instances, how-
ever, a direct correlation between these
exposures and cancer development are
difficult to make.
Nonrandom aggregations of cancer
have been recognized to occur since the
middle of the last century. Although
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almost every type of cancer has been
reported to occur in a familial form, evi-
dence ofhereditary and familial influences
exist in only a few percent ofcases (1). The
actual fraction of human cancers that are
due to genetic and familial factors is not
known; however, more than 100 single-
gene disorders, including autosomal domi-
nant, recessive, and X-linked conditions
have been associated with a high risk of
cancer development. Some ofthese pheno-
types are represented primarily by the devel-
opment of cancer clustering in families,
whereas in others such as ataxia-telangecta-
sia, cancer appears to occur as a secondary
event. In fact, as it turns out, the genetic
events leading to cancer development in
this disorder may not be dissimilar from
those associated with molecular carcino-
genesis in sporadic malignancies. Certain
cancers, such as retinoblastoma, a rare eye
tumor of childhood, appear to arise pri-
marily through inherited (germline)
genetic alterations that are passed from
parent to child, while others, including
cancers ofthe lung, bladder, and oral cav-
ity develop as a result of interactions
between intracellular acquired (somatic)
genetic changes induced by external
environmental signals.
Epidemiologic studies have demon-
strated that some people carry in their
genes a predisposition to develop cancer.
Often this genetic predisposition leads to
an increased likelihood ofsuffering from a
specific cancer or group of cancers com-
pared to the general population. Although
individuals with well-defined cancer family
syndromes account for only a small minor-
ity (perhaps 0.1% of all people with can-
cer), those patients belonging to families
with cancer where heredity plays some role
may account for up to 10% ofall cancer.
The most characteristic feature ofhereditary
cancers is the tendency for their early age of
onset. In addition, it is not at all unusual to
find affected children in these kindreds. In
addition to the significant questions sur-
rounding potential detection ofgenetic pre-
disposition to cancer in individuals at high
risk, the study of hereditary cancers and
cancer families has led to the detection ofa
class ofgenes critical both in carcinogenesis
and normal development (2).
Faulty regulation ofcellular growth and
differentiation leads to neoplastic transfor-
mation and tumor initiation. Many inap-
propriately activated growth-potentiating
genes, or oncogenes, have been identified
through the study of RNA tumor viruses
and the transforming effects of DNA iso-
lated from malignant cells. Mutations in
oncogenes tend to occur in one ofthe two
alleles ofthe gene, and act in a dominant
manner to the wild-type (normal) allele.
These are, in effect, "gain of function"
mutations that constitutively or perma-
nently signal the cell to divide. Activated
dominant oncogenes, however, do not
themselves readily explain a variety ofphe-
nomena related to transformation and
tumor formation. Among these are suppres-
sion oftumorigenicity by fusion ofmalig-
nant cells with their normal counterparts,
tumor-associated specific chromosome
deletions, and the existence ofhereditary
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forms of cancer, as described above. In
fact, although mutations in oncogenes
appear to arise spontaneously in somatic
tissues over the lifetime of the organism,
naturally occurring inherited forms of
these mutations are not known.
Comparisons between the frequencies
offamilial tumors and their sporadic coun-
terparts led Knudson to suggest that famil-
ial forms of some tumors could be
explained by constitutional mutations in
growth-limiting genes. The resulting inac-
tivation of these genes would facilitate
cellular transformation. Inactivations of
these growth-limiting, or tumor suppres-
sor, genes are the result either ofmutations
in both alleles or a mutation in one allele
followed by a loss of, or a "reduction to
homozygosity," in the second. Unlike the
dominant oncogenes, mutant tumor sup-
pressor genes may be present in either germ
cells or somatic cells. In the former, they
may arise spontaneously in the gamete or
be transmitted from generation to genera-
tion within a family. Although studies have
located the chromosomal sites of many
putative tumor suppressor genes, only a
few have been isolated to date. These
include the retinoblastoma susceptibility
gene (RBI), the Wilms tumor gene
(WTI), p53 in the Li-Fraumeni family
cancer syndrome, genes associated with the
development ofcolon carcinoma [adeno-
matous polyposis coli (APC), mutated in
colon cancer (MCC)], and the gene associ-
ated with neurofibromatosis. Although the
function ofthe protein encoded by each of
these genes differs, they all share the prop-
erties associated with suppression of cell
growth and proliferation.
The paradigm for early age of onset of
cancer in extended pedigrees is the Li-
Fraumeni syndrome (3). This disorder, first
characterized in 1969, is now classically
represented by the presence of a proband
with sarcoma under the age of45, a first-
degree relative who develops a sarcoma
before the age of45 years, and a second
first-degree relative with cancer ofany type
diagnosed under the age of45 years. Other
frequently occurring tumors include breast
cancer, acute leukemias, brain tumors, car-
cinomas ofthe adrenal cortex, and osteosar-
comas. Often it is found that affected
family members who survive their first
tumor go on to develop a second malig-
nancy that is different in its histopathology
from the first. It is very common to dis-
cover several tumors in different affected
family members that occur at ages earlier
than expected for the general population
(4). Heritable germline mutations of the
p53 tumor suppressor gene have been
described in probands ofLi-Fraumeni syn-
drome families and both affected and
young unaffected relatives (5,6). In addi-
tion, occasional germline p53 mutations
have been described in patients not belong-
ing to Li-Fraumeni kindreds but who have
multifocal osteogenic sarcoma, multiple
primary malignancies, and to a very much
lesser degree, breast cancer. Several studies
are ongoing in other populations ofcancer
patients to determine the genetic hetero-
geneity ofLi-Fraumeni syndrome, and the
high-risk cancer populations likely to har-
bor a genetic predisposition to the cancers
theydevelop.
The very high probability of develop-
ing cancer in individuals, and in particular
children, who carry germline alterations of
tumor suppressor genes has led to the pos-
sibility ofpredictive genetic testing in unaf-
fected relatives. It is now technically
feasible to perform such testing in many
molecular biology laboratories worldwide.
However, with the imminent identification
ofmany more genes for hereditary diseases,
including cancer, many of which will
directly affect children, the proper use of
the genetic information in both individuals
and the population is a matter ofgrowing
concern. Many issues, such as autonomy,
confidentiality, and nondiscrimination, are
generic to testing for any heritable disease.
For adult-onset genetic disorders such as
Huntington's or Alzheimer's disease, the
issue of testing children is less frequently
found to be at issue. However, for diseases
such as cancer, for which primary preven-
tive measures may be available, predictive
testing of children raises important
concerns (7,8).
One ofthe most widely discussed and
evaluated testing "programs" has been that
ofp53 testing in high-risk patients, includ-
ing those who belong to classic Li-
Fraumeni families, those who belong to
families with cancer histories resembling
this syndrome, and individuals who are rel-
atives of patients with characteristic fea-
tures of the syndrome in the absence ofa
family history ofcancer. These risk groups,
as examples ofchildren and young adults
who might benefit or suffer from such test-
ing, are discussed in more detail elsewhere
in the symposium.
I present here recommendations that
should be considered in the development
ofpredictive genetic testing policies for
cancer in children andyoungadults (9):
* Predictive testing for germline muta-
tions of genes associated with cancer
predisposition should be performed
only in pilot research programs with the
availability ofknowledgeable psychoso-
cial, genetic, medical, and oncologic
counseling, as well as established
molecular screening laboratories with
expertise in the interpretation of the
biological significance of observed
genetic alterations.
. Within the above research settings, pre-
dictive testing should be offered only to
close relatives of cancer patients in
whom a germline gene mutation has
been previously identified. Such testing
should be undertaken only after appro-
priate counseling on the benefits and
limitations of testing (both technical
and interpretive) has been provided.
* Predictive genetic testing on cancer
patients or the general population should
not be undertaken outside defined
research settings; the harmful potential
of such testing far outweighs the
benefits. Furthermore, the carrier rate for
most ofthe currently isolated cancer-pre-
disposing genes is demonstrablylow.
* It is critical that appropriate counseling
be given to carriers ofmutant genes and
their relatives regarding the seeking of
early medical attention for signs and
symptoms of cancer and pursuit of
healthy lifestyle.
* Further study ofthe impact ofpredic-
tive testing on children within the lim-
ited research settings outlined above
should be carried out.
There are many gaps in our knowledge
ofthe role ofgenetic predisposition in can-
cer development, and many drawbacks of
predictive testing as it is currently available.
Nonetheless, the possibility ofreducing the
marked loss ofhuman potential resulting
from the death of a child or young adult
makes pilot research efforts for early inter-
vention in carriers ofgermline mutations of
cancer-predisposing genes worthwhile.
Further studies into the development of
more accurate testing procedures, under-
standing ofthe effect ofgermline mutations
on cell transformation and tumor forma-
tion, and perhaps the development ofani-
mal models will continue to be important.
In addition, studies ofevaluation ofcancer
risk notification addressing this process, the
impact ofknowledge, attitudes, emotions,
and disease and health status outcomes are
required (10). Ultimately, one would hope
that these studies lead through screening to
the early detection and successful treatment
ofcancer in children andyoungadults.
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